Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice
Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice
复制标题
阿达木单抗对溃疡性结肠炎患者的长期疗效和安全性评估：6 年真实临床实践的结果
DOI：
10.1159/000493121
复制
发表时间：
2018
影响因子：
2.3
通讯作者：
Hanai Hiroyuki
中科院分区：
文献类型：
--
作者：
Sugimoto Ken;Ikeya Kentaro;Kato Masaichi;Matsuura Ai;Watanabe Fumitoshi;Takano Ryosuke;Tamura Satoshi;Tani Shinya;Osawa Satoshi;Hanai Hiroyuki
背景虽然阿达木单抗在溃疡性结肠炎（UC）患者中的中短期疗效的证据正在出现，但阿达木单抗长期疗效的报告数量有限。本研究旨在了解基线人口统计学特征，这些特征可能是阿达木单抗诱导UC患者缓解后复发或结肠切除术的风险因素。此外，影响长期outcomes的因素是identified.MethodsTwenty-one UC患者谁曾与阿达木单抗治疗进行了回顾性分析。比较分析进行了因素类固醇撤退与非撤退，长期缓解与复发后缓解，并需要手术干预UC与surgery-free. Results阿达木单抗治疗与类固醇递减在类固醇依赖的情况下，在长期。在14例临床缓解的患者中，350周的累积无复发生存率为43.8%，累积非手术生存率为85.7%。手术的危险因素包括不耐受水杨酸盐（p= 0.005）和过去的治疗与他克莫司（p= 0.023）。ConclusionsAdalimumab治疗与长期疗效的患者轻度UC患者实现了高累积非手术生存率在一个很长的时间，超过6年。
BackgroundAlthough evidence for the short-to medium-term efficacy of adalimumab in ulcerative colitis (UC) patients is emerging, there are a limited number of reports on the long-term efficacy of adalimumab. This study was to understand baseline demographic features, which potentially could be risk factors for relapse or colectomy following induction of remission by adalimumab in UC patients. Additionally, factors affecting long-term outcomes were to be identified.MethodsTwenty-one patients with UC who had been treated with adalimumab were reviewed retrospectively. Comparative analyses were undertaken by factoring steroid withdrawal versus non-withdrawal, long-term remission versus relapse following remission, and requiring surgical intervention for UC versus surgery-free.ResultsAdalimumab treatment was associated with steroid tapering in steroid-dependent cases in the long term. Of the 14 patients in whom clinical remission was achieved, the cumulative nonrelapse survival rate at 350 weeks was 43.8% and the cumulative nonoperative survival rate was 85.7%. Risk factors for surgery included intolerance to salicylates (p= 0.005) and past treatment with tacrolimus (p= 0.023).ConclusionsAdalimumab treatment was associated with long-term efficacy in patients with mild UC–patients achieved a high cumulative nonoperative survival rate over a long period of time, beyond 6 years.
登录
查看更多内容
他克莫司治疗类固醇难治性溃疡性结肠炎的短期疗效 – 130 名患者的经验
影响因子：
7.6
作者：
K. Schmidt;K. Herrlinger;J. Emmrich;D. Barthel;H. Koç;Hendrik Lehnert;E. Stange;K. Fellermann;J. Büning
通讯作者：
J. Büning
阿达木单抗治疗溃疡性结肠炎：巴西多中心观察研究的结果。
影响因子：
--
作者：
P. Zacharias;A. Damião;A. Moraes;F. Teixeira;J. Ludvig;R. Nones;R. Saad;L. Sassaki;Rosemary da Silva;L. Facchin;M. Olandoski;P. Kotze
通讯作者：
P. Kotze
影响因子：
12.6
作者：
Arias, Maria Theresa;Casteele, Niels Vande;Ferrante, Marc
通讯作者：
Ferrante, Marc
影响因子：
24.5
作者：
Ogata, H.;Matsui, T.;Hibi, T.
通讯作者：
Hibi, T.
影响因子：
2.6
作者：
E. Szigethy;L. McLafferty;A. Goyal
通讯作者：
E. Szigethy;L. McLafferty;A. Goyal